Apolipoprotein E (apoE) may act as a vasculoprotective factor by promoting plasma lipid clearance and cholesterol efflux. Moreover, apoE accumulates at sites of vascular injury and modulates the effect of growth factors on smooth muscle cells (SMCs). Experimental data suggested that hypothalamic apoE expression is reduced in obesity and associated with leptin resistance. In this study, we examined the role of apoE in mediating the effects of leptin on vascular lesion formation.
Introduction
Clinical and experimental evidence suggests that the adipokine leptin may directly link obesity with the elevated cardiovascular risk associated with increased body weight. For example, we and others have shown that mice lacking leptin (ob/ob) or its receptor (db/db) were protected from neointima formation in response to vascular injury, whereas exogenous administration of leptin promoted experimental lesion formation in a receptor-specific manner. 1 -3 On the other hand, findings regarding the role of this adipokine during atherosclerotic lesion formation are less consistent. Administration of recombinant leptin into apolipoprotein E-deficient (apoE 2/2 ) mice was found to promote 4 or not † Present address: Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany. ‡ Present address: Center for Thrombosis and Hemostasis, University Medical Center Mainz, Mainz, Germany.
to alter 5 atherosclerosis. Similarly, lack of both apoE and leptin or its receptor resulted in either increased 6 or reduced 7 atherosclerosis progression, although findings may have been obscured by the associated massive elevation of plasma lipid levels. Apolipoprotein E (apoE) is a major component of lipoproteins. After binding to specific receptors on liver and other cells, it mediates plasma lipid clearance and transmembrane reverse cholesterol transport. ApoE 2/2 mice develop severe hypercholesterolaemia and are widely used as model system to study the pathophysiology of atherosclerosis. 8 In addition to the liver, brain or adipose tissue, apoE is also produced by vascular cells, including smooth muscle cells (SMCs). 9 Vascular injury induces the passive accumulation as well as local synthesis of apoE within the vessel wall, 10 where it may modulate SMC migration and proliferation 11 and neointima formation. 12 Interestingly, the expression of apoE within adipose tissue 13 or hypothalamus 14 appears to be regulated by the nutritional status and was recently found to be reduced in obesity. Moreover, central apoE administration was shown to act as satiety signal suppressing food intake and reducing body weight. 14 Of note, exogenous leptin was less efficacious in mice lacking apoE implicating reduced apoE as a potential mediator of the leptin resistance frequently associated with increased body weight. 15 To examine the hypothesis that apoE may be involved in mediating the effects of leptin on vascular lesion formation, recombinant murine leptin was administered into apoE 2/2 mice followed by the analysis of neointima formation (in response to FeCl 3 -induced vascular injury) and atherosclerotic lesion development, respectively. To study the mechanisms underlying our finding that the absence of apoE resulted in the inability of leptin to promote vascular lesion growth, in contrast to findings in WT and LDL-R 2/2 mice analysed in parallel, WT or apoE 2/2 mouse or human arterial SMCs after siRNA-mediated downregulation of cellular apoE expression were functionally and biochemically examined.
Methods
A detailed method section is provided as Supplementary material online.
Experimental animals
Male mice deficient for apolipoprotein E (apoE 2/2 ), low-density lipoprotein (LDL) receptor (LDL-R 2/2 ) or caveolin-1 (cav-1 2/2 ) were from Jackson Laboratories. Wild-type (WT) mice (C57Bl/6J) were obtained from Harlan Winkelmann. At the age of 10 weeks, apoE 2/2 mice were either switched to high-cholesterol diet (HCD; TD88137; Harlan) or maintained on normal rodent chow (Ssniff) until tissue harvest (i.e. 5 weeks for neointima formation and 8 weeks for spontaneous atherosclerosis). Hyperleptinemia was produced by administration of recombinant murine leptin (R&D Systems) via osmotic minipumps (Alzet; Charles River Laboratories) or intraperitoneal injection, as indicated in the text. Pumps were subcutaneously implanted under inhalational anaesthesia with 2% isoflurane (Forenew, Abbott). The depth of anaesthesia was monitored by observation of the respiratory rate or the toe-pinch reflex test. To study the effects of leptin on neointima formation, mice were treated for 1 week before being subjected to carotid artery injury using 10% FeCl 3 and for additional 3 weeks until tissue harvest (i.e. a total of 4 weeks). To study the effects of leptin on atherosclerosis, apoE 2/2 mice were treated for 8 weeks with pumps being exchanged after 4 weeks. For tissue harvest, mice were deeply anaesthetized with 2% isoflurane and killed by perfusion with 4% zinc formalin (ThermoShandon). The carotid artery, brachiocephalic artery and aortic root were excised and embedded in paraffin. The study conformed with the Directive 2010/63/EU of the European Parliament. All animal experimental procedures were approved by local authorities and complied with national and institutional guidelines for the care and use of laboratory animals.
Plasma parameter
Heparin-anticoagulated blood was obtained by cardiac puncture at tissue harvest. Plasma was prepared by centrifugation at 800 g for 5 min. Cholesterol and triglyceride levels were determined spectrophotometrically (Thermo Electron Corporation). Leptin levels were measured using specific enzyme-linked immunoassays (R&D Systems).
Smooth muscle cells
Human arterial SMCs (HASMCs; Lonza) were maintained in SMC growth medium (Lonza) supplemented with 5% foetal calf serum (FCS). HASMCs were transfected with siRNA against either human apoE, cav-1, or scrambled (scr) siRNA (all Santa Cruz Biotechnologies) using metafectene SI transfection reagent (Biontex) and analysed 72 h later. Murine aortic SMCs (MASMCs) were isolated from the thoracic aortas of male apoE 2/2 and C57Bl/6J WT mice and cultured in DMEM/F12 Glutamax (Invitrogen) containing 10% FCS, 100 U/mL penicillin, and 100 mg/mL streptomycin. From passage 2 onwards, MASMCs were maintained in SMC growth medium.
Cell proliferation
SMC proliferation was analysed using the CellTiter 96w AQ ueous One Solution kit (Promega). In some experiments, cells were treated for 30 min with signal transduction inhibitors, ROS scavengers, NADPH oxidase inhibitors, or cholesterol-depleting reagents prior to leptin stimulation.
Flow cytometry
SMCs (1 × 10 6 cells) were incubated with fluorescein isothiocyanateconjugated antibodies against human ObR (R&D Systems). Specificity experiments were performed using neutralizing antibodies against leptin (anti-Ob; R&D Systems) or non-specific IgG controls. To measure the formation of reactive oxygen species (ROS), cells were stimulated with leptin, angiotensin II (AngII), platelet-derived growth factor (PDGF), or thrombin, followed by loading with dichlorodihydrofluorescein diacetate (DCF-DA; Invitrogen).
RNA preparation and polymerase chain reaction
The total RNA from SMCs was extracted using TRI Reagent (Ambion) and reverse transcribed into cDNA. The semi-quantitative polymerase chain reaction (RT -PCR) was carried out to assess the mRNA expression of cyclin D1 or the short-and long isoform of the leptin receptor. The relative pixel intensity of the target gene band was normalized to b-actin. The primer sequences used for phenotyping MASMCs are shown in the Supplementary material online, Table S1 .
Protein isolation, cell fractionation and western blot analysis
HASMCs were resuspended in lysis buffer containing fresh protease and phosphatase inhibitors. After incubation for 20 min on ice, cell lysates were cleared by centrifugation followed by protein determination (BioRad). For immunoprecipitation, 100 mg of total cell lysates were precleared with nProtein A Sepharose TM 4 Fast Flow beads (GE Healthcare), followed by incubation with 2 mg specific antibody under rotary agitation overnight. Equal amounts of protein were loaded and fractionated by SDS gel electrophoresis and transferred to nitrocellulose membranes. Following blocking, membranes were incubated with primary antibodies overnight at 48C. Protein bands were visualized using HRP-conjugated secondary antibodies (Amersham Biosciences), followed by HRP detection with enhanced chemiluminescent substrate (Fisher Thermo Scientific). For cell fractionation, 3 × 10 6 flash frozen cells were extracted using ProteoExtractw Subcellular Proteome Extraction kit (Calbiochem).
Statistical analysis
Data are presented as the mean + SEM. The normal distribution was tested using the D'Agostino and Pearson omnibus normality test. If values were normally distributed, differences between two groups were tested by Student's t-test for unpaired means, differences between more than two groups using ANOVA followed by Bonferroni's multiple comparison test. If results did not follow a normal distribution, differences were compared using the Mann-Whitney or Kruskall-Wallis test followed by Dunn's post hoc analysis, respectively. Statistical significance was assumed when P reached a value ,0.05. All statistical analyses were performed using GraphPad Prism software, version 4.01.
Results

Leptin promotes vascular lesion formation in WT mice, but not in mice lacking apoE
To study the importance of apoE in modulating the vascular response to leptin, osmotic minipumps containing recombinant murine leptin or normal saline (control) were implanted under the dorsal skinfold of 10-week-old chow-fed apoE 2/2 mice (plasma leptin at tissue harvest:
9.3 + 2.7 vs. 1.2 + 0.3 ng/mL in controls; P , 0.001). Morphometric analysis revealed that leptin did not alter neointima formation, whereas lumen narrowing was significantly enhanced in apoE 2/2 mice fed HCD ( Figure 1A , representative findings in D). Similar results were obtained for the neointima area and intima-to-media ratio (not shown). Since we have previously shown that leptin (administered daily i.p. over 3 weeks) promotes neointima formation in WT and leptindeficient ob/ob mice, 1 leptin was administered to apoE 2/2 mice also via daily i.p. injections. Again, leptin had no effect on lumen stenosis in mice lacking apoE, whereas a significant increase was observed in leptintreated WT mice analysed in parallel ( Figure 1B Figure S2C ) also were significantly increased in lesions of leptintreated WT mice, but not in their apoE-deficient counterparts. Of note, vascular remodelling was more pronounced ( Figure 1B ) and the a-actin-positive ( Figure 1E ) or sirius red-positive (Supplementary material online, Figure S2C ) neointima are greater in control-treated apoE
vs. WT mice. The total (906 + 145 vs. 186 + 15 mg/dL; P , 0.001) and LDL (276 + 13 vs. 116 + 11 mg/dL; P , 0.001) cholesterol levels were elevated in HCD-fed apoE 2/2 mice compared with their chow-fed counterparts, and leptin did not affect both parameters (total cholesterol: 202 + 41 mg/dL; LDL cholesterol: 138 + 36 mg/dL; P ¼ 0.495 and P ¼ 0.671 vs. apoE 2/2 mice, respectively). Plasma leptin levels in HCD-fed mice were 11 + 2.1 ng/mL (P , 0.001 vs. control-and P ¼ 0.580 vs. leptin-treated mice).
Leptin promotes SMC proliferation via NADPH activation and ROS generation
To further examine the mechanisms underlying the above findings regarding the differential effects of leptin on neointima formation in WT and apoE 2/2 mice and their potential relevance for human vascular pathologies, analyses were performed in cultivated human arterial SMCs (HASMCs). Flow cytometry (Supplementary material online, Figure S3A ; 44 + 3.2% positive cells) and RT -PCR (Supplementary material online, Figure S3B ) confirmed that HASMCs express the leptin receptor (ObR). Recombinant human leptin dose-(from 1 to 100 ng/mL; Supplementary material online, Figure S3C ) and time dependently (from 24 to 72 h; Supplementary material online, Figure S3D ) increased HASMC proliferation, and findings were confirmed by the detection of elevated cyclin D1 mRNA levels in leptin-compared with control-stimulated cells (Supplementary material online, Figure S3E ). Stimulation of HASMCs with leptin induced the phosphorylation of Src kinase (Supplementary material online, Figure S4A ), protein kinase B (Akt; Supplementary material online, Figure S4B ), p42/44 MAP kinase (ERK1/2; Supplementary material online, Figure S4C ), protein kinase C (PKC; Supplementary material online, Figure S4D ) and STAT3 (Supplementary material online, Figure  S4E ), and preincubation with inhibitors of either Src kinase (i.e. PP2 and SU6656), Akt (i.e. Ly294002), ERK1/2 (i.e. PD98059), PKC (i.e. calphostin C) or STAT3 inhibitor peptide confirmed their role in mediating the effects of leptin on SMC proliferation (Supplementary material online, Figure S4F ). Furthermore, flow cytometry ( Figure 2A ; 190 + 12% positive cells) and fluorescence microscopy ( Figure 2B ) revealed that stimulation of HASMCs with leptin (100 ng/mL leptin for 60 min) increased the generation of ROS. This effect could be inhibited by preincubation with monoclonal leptin-neutralizing antibodies ( Figure 2A ) and was comparable with SMC mitogens known to act via ROS ( Figure 2B ). 16 Preincubation with the ROS scavengers superoxide dismutase (SOD) and catalase abolished the HASMC proliferation in response to leptin ( Figure 2C ), and similar findings were obtained using apocynin or diphenyleneidodonium (DPI), pointing to a role of NADPH oxidases in the leptin-induced ROS generation and SMC proliferation. In this regard, stimulation of HASMCs with leptin increased the phosphorylation of p47 phox ( Figure 2D ), a final common pathway in NADPH oxidase assembly and activation. 17 SMCs isolated from the thoracic aorta of WT mice also exhibited a significantly increased proliferation (Supplementary material online, Figure S7A ) and ROS production (Supplementary material online, Figure S7B and C) in response to leptin.
ApoE is required for the leptin-induced NADPH activation, ROS formation and SMC proliferation
To study the role of apoE in modulating the effects of leptin, HASMCs were transfected with specific siRNAs to transiently down-regulate apoE mRNA ( Figure 3A ) and protein ( Figure 3B ) expression, followed by stimulation with recombinant human leptin (100 ng/mL). ApoE siRNA transfection did not alter the surface ObR expression ( Figure 3C ), but prevented the phosphorylation of ObR (not shown) and STAT3 (Supplementary material online, Figure S5A ) in response to leptin. Similar findings were obtained for the leptin-induced increase of phosphorylated Akt (Supplementary material online, Figure S5B ), ERK1/2 (Supplementary material online, Figure S5C ), PKC (Supplementary material online, Figure S5D ), and p47 phox ( Figure 3D ), whereas Src kinase continued to be phosphorylated in response to leptin (Supplementary material online, Figure  S5E ). Importantly, apoE down-regulation or genetic deficiency abolished the effects of leptin on HASMC proliferation ( Figure 4A and Supplementary material online, Figure S7A ), cyclin D1 mRNA expression ( Figure 4B) , and ROS formation ( Figure 4C and Supplementary material online, Figure S1B and C). Consistent with apoE being secreted and binding to heparin-rich proteoglycans (HSPG) on the cell surface, crossover incubation with conditioned medium (CdM) from apoE siRNAtransfected HASMCs ( Figure 4D ) or pre-treatment of HASMCs with heparinase ( Figure 4E ) also abolished the effects of leptin on proliferation.
3.4 The effects of leptin on SMC proliferation and neointima formation require intact cholesterol-rich cell membranes and caveolin-1
Since preincubation with the cholesterol chelator methyl-b-cyclodextrin (MbCD), known to disrupt the structure of caveolae, also abolished the effects of leptin on ROS production (Supplementary material online, Figure S4A ) and HASMC proliferation (Supplementary material online, Figure S4B ), further analyses on the role of apoE in mediating the effects of leptin were focusing on cholesterol-rich cell membrane microdomains. The stimulation of HASMCs with leptin strongly enhanced the phosphorylation of caveolin-1 (cav-1; Figure 5A ), a major coat protein required for caveolae assembly and expressed in SMCs. 18 Moreover, leptin increased the accumulation of cav-1 within the cell membrane of HASMCs, as shown by immunocytochemistry ( Figure 5B ) and cell fractionation ( Figure 5C ). Leptin-induced cav-1 membrane translocation was also observed in aortic SMCs isolated from WT mice, but not in those from their apoE 2/2 counterparts (Supplementary material online, Figure S7D ). Immunoprecipitation analysis of HASMCs revealed that cav-1 co-localized with ObR and Src kinase, and the latter interaction was reduced following apoE siRNA transfection ( Figure 5D ). The effects of leptin on cav-1 phosphorylation ( Figure 5E ) and cell membrane accumulation (not shown) were abolished by siRNA-mediated down-regulation of apoE. Importantly, siRNAmediated down-regulation of cav-1 in HASMCs ( Figure 6A ) prevented the effects of leptin on SMC proliferation ( Figure 6B) . Moreover, leptin failed to promote neointima formation in cav-1 2/2 mice ( Figure 6C ), suggesting that changes in membrane integrity and caveolae composition may underlie the observed absence of vascular effects of leptin in mice or SMCs lacking apoE.
Figure 2 Effects of leptin on NADPH oxidase activation and ROS formation in HASMCs. (A) Flow cytometry revealed increased ROS production in
HASMCs exposed to leptin (100 ng/mL, 60 min), and this effect was abolished by leptin-neutralizing antibodies. A representative histogram of seven independent experiments is shown. (B) Fluorescence microscopy demonstrated that the effects of leptin (100 ng/mL) were comparable with those of AngII (100 nM), PDGF (100 ng/mL), or thrombin (0.1 mU/mL). Size bars denote 250 mm. The mean DCF fluorescence (as determined by flow cytometry) is also indicated. *P , 0.05 vs. controls set at 1. (C) HASMC proliferation in response to leptin (100 ng/mL) could be prevented by preincubation with SOD and catalase (1 U/mL each), apocynin (300 mM), or DPI (25 mM) (three independent experiments). ***P , 0.001 vs. controls set at 1; #P , 0.05, ## P , 0.01 and ### P , 0.001 vs. leptin. (D) Western blot analysis (seven independent experiments) revealed that leptin (100 ng/mL) time dependently increased the phosphorylation of the NADPH subunit p47 phox . *P , 0.05 vs. untreated cells set at 1.
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Discussion
The main findings of this study are that the effects of leptin on vascular lesion formation and mitogenic signalling in SMCs involve intact cholesterol-rich cell membrane microdomains and require the presence of apoE and cav-1. Using a human cell line as well as primary murine SMCs, isolated from the aorta of WT and apoE 2/2 mice, we show that leptin promotes the activation and membrane translocation of cav-1 and induces p47 phox phosphorylation, ROS generation and SMC proliferation. Moreover, down-regulation of cellular apoE expression (using siRNA), cleavage of cell surface-bound apoE (using heparinase) or caveolae disruption (using MbCD) were found to abolish the effects of leptin on NADPH oxidase activation, ROS formation and SMC proliferation. Importantly, we demonstrate that apoE or cav-1 deficiency was associated with the absence of vascular lesion-promoting effects of leptin in vivo.
A role for leptin in vascular lesion formation was first suggested by findings that db/db mice (which lack the leptin receptor) did not develop neointimal hyperplasia despite the presence of obesity and diabetes. 3 Similarly, leptin-deficient ob/ob mice were protected from neointima formation, whereas the exogenous administration of the adipokine restored the vascular phenotype in ob/ob, but not in db/db mice.
1,2
Because ob/ob mice do not spontaneously develop atherosclerotic lesions, even after being placed on cholesterol-rich diet, 19 they have been crossed into the apoE 2/2 background. Although offsprings exhibited accelerated atherosclerosis progression, disruption of leptin Figure 3 The effect of apoE down-regulation on leptin-induced signalling in HASMCs. ApoE expression in HASMCs was transiently reduced using apoEspecific siRNAs. Representative examples of the apoE (A) mRNA and (B) protein expression 72 h after transfection with apoE or scrambled (scr) control siRNA and the summary of three to five independent experiments are shown. (C) Flow cytometry revealed that apoE siRNA transfection did not alter ObR expression. The statistical analysis and representative histograms of four independent experiments are shown. Western blot analysis was performed to examine the effect of apoE down-regulation on the leptin-induced (100 ng/mL) increase in (D) p47 phox phosphorylation (four to six independent experiments). **P , 0.01 and ***P , 0.001 vs. control-treated, src siRNA-transfected cells; ## P , 0.01 vs. leptin-stimulated, scr siRNA-transfected cells.
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signalling was associated with severe dyslipidaemia and more pronounced diabetic features, which may have masked any direct effects of the adipokine. 6 Supporting the hypothesis that atherosclerosis in this mouse model is primarily driven by the associated hyperlipidaemia, atherosclerosis in ob/ob x apoE 2/2 mice decreased after reconstitution of apoE expression in bone marrow-derived macrophages and subsequent reduction of plasma lipid levels. 20 To directly examine the role of leptin on vascular lesion formation in atherosclerosis-prone mice, we administered recombinant leptin into apoE 2/2 mice using osmotic minipumps. However, no effects of leptin on neointimal lesions developing in response to experimental vascular injury were observed. Parallel analysis of WT and LDL-R 2/2 mice suggested that leptin requires the presence of apoE to promote vascular lesion growth. Similarly, no differences in atherosclerotic lesion size were detected between control-and leptin-treated apoE 2/2 mice examining three typical localizations. Whereas our observations are in contrast to a previous study reporting that daily i.p. injections of recombinant leptin (at 10-fold higher concentrations) into high fat diet-fed apoE 2/2 mice enhanced atherosclerosis, 4 they are in agreement with others showing no effect of leptin on atherosclerotic lesion size or surface area 5 or inhibition of lesion progression. 21 Of note, the leptin dosage of the present study matched those used in previous ones showing that the adipokine promotes neointima hyperplasia. 1 SMCs constitute the primary component of vascular lesions, and we and others have shown that leptin promotes their proliferation in vitro. 1, 22 In this regard, vascular lesions of leptin-treated WT mice were characterized by higher numbers of a-actin-or PCNA-positive cells as well as a higher collagen content compared with controls, whereas no changes were detected in their leptin-treated apoE 2/2 counterparts. We now confirm and extend those findings showing Figure 4 Importance of apoE expression, secretion and cell surface binding in mediating the effects of leptin. HASMCs were transfected with apoE or scr control siRNA and the effects of leptin (100 ng/mL) on (A) cell proliferation, (B) cyclin D1 mRNA expression (after normalization for b-actin mRNA expression) and (C) ROS formation examined. Results are expressed -fold increase of control-treated cells (set at 1). Proliferation was also examined after (D) incubation with CdM from apoE siRNA-transfected HASMCs or (E) pre-treatment of HASMCs with heparinase. *P , 0.05, **P , 0.01 and ***P , 0.001 vs. control-treated cells; #P , 0.05 and ## P , 0.01 vs. leptin-stimulated, scr siRNA-transfected cells.
Schroeter, leptin, cav-1, and neointima formation that leptin induced the activation of signal mediators (e.g. Akt, ERK1/2) required to promote the G 0 to G 1 cell-cycle transition (e.g. cyclin D1). Moreover, leptin's effects on SMCs were found to involve NADPH oxidase activation (as indicated by p47 phox phosphorylation) and ROS formation, and ROS scavengers and NADPH oxidase inhibitors confirmed their role in the leptin-induced SMC proliferation. The effects of leptin were comparable with AngII, thrombin, or PDGF, i.e. mitogenic stimuli known to act via ROS formation and p47 phox activation. 16 Previous studies have established that p47 phox is necessary for growth factor-induced SMC proliferation and atherosclerosis progression, 23 and p47 phox deficiency was shown to abolish the effects of leptin on endothelial ROS generation. 24 28 and our studies also show that the effects of leptin on ROS formation (not shown) and SMC proliferation could be abrogated using inhibitors of the above signalling molecules. Importantly, the effects of leptin on SMC proliferation, cyclin D1 expression, and ROS formation were found to be absent in aortic SMCs isolated from apoE 2/2 mice and could be abolished by siRNA-mediated knockdown of apoE expression in a human SMC line, consistent with the observed lack of leptin on vascular lesion formation in apoE 2/2 mice. Down-regulation of apoE also inhibited the activation of Akt, PKC, ERK1/2, and p47 phox in response to leptin, whereas it did not alter the leptin-induced activation of Src kinase. On the other hand and as discussed below, apoE siRNA transfection reduced the interaction of Src kinase and cav-1 and thus may disrupt specific downstream signalling. Although studies in cultivated SMCs may not accurately mimic the in vivo situation, it should be noted that systemic apoE deficiency is accompanied by confounding factors, such as hyperlipidaemia or increased oxidative stress, making it difficult to distinguish any direct effects. ApoE is important during atherosclerotic lesion formation, as suggested by findings that apoE 2/2 mice develop extensive vascular lesions, 8 whereas those overexpressing apoE are resistant to atherosclerosis. 29 Interestingly, in vivo studies indicated that the vasculoprotective effects of apoE may be independent of its function in plasma lipid clearance. 30 Studies using purified protein demonstrated that apoE may inhibit PDGF-induced SMC proliferation and migration 11 by preventing MAPK activation, cyclin D1 mRNA expression, and early G1 phase progression. 31 Of note, our analyses focused on the role of apoE in modulating the leptin-induced mitogenic signalling in SMCs and not the effects of apoE or lack thereof per se. In line with our findings that apoE deficiency or knockdown are associated with the inability of leptin to promote SMC proliferation and neointima formation, exogenous leptin was recently reported to be less efficacious (regarding food intake and weight loss) in mice lacking apoE. 15 ApoE circulating in plasma binds to lipoprotein receptors and HSPGs expressed on the surface of liver and other cells, including SMCs. Previous studies demonstrated that the effects of apoE on SMC migration are Schroeter, leptin, cav-1, and neointima formation mediated via LDL-R-related protein 1, whereas those on SMC proliferation involve the binding of apoE-enriched lipoproteins to HSPGs. 32 In this regard, we found that the absence of LDL-R, one of the main cellular receptors for apoE, did not prevent the effects of leptin on neointima formation, whereas SMC proliferation in response to leptin was abolished by genetic apoE deficiency or siRNA-mediated down-regulation of cellular apoE expression as well as heparinase pre-treatment, i.e. HSPG cleavage and removal of cell surface-bound apoE. Moreover, cross-over incubation of HASMCs with CdM from apoE siRNAtransfected cells suggested that the lack of secreted apoE also impairs the effects of leptin. While in the present study only homotypic responses were examined, future analyses will have to explore whether secreted apoE may affect other vascular cell types, e.g. macrophages or endothelial cells. Membrane cholesterol depletion also abolished leptin's effects on ROS formation and SMC proliferation, pointing to a role for caveolae in leptin signalling. Caveolae are small, lipid-rich cell membrane microdomains involved in cholesterol transport and signal transduction. By forming oligomers with receptors and other signalling mediators, they serve as scaffolding proteins involved in the organization and functional compartmentalization of signalling complexes within the cell. Caveolar signalosomes have been shown to contain G-protein-coupled receptors and receptor tyrosine kinases, and PI3, Src, or p42/44 MAP kinase also localize to caveolin-rich membrane fractions. 33 Caveolins are transiently phosphorylated during growth factor signalling, and previous studies highlighted their importance in the mitogenic signalling in response to PDGF, 34 endothelin-1, or stretch. 35 SMCs primarily express cav-1 and -3, 18 and immunoprecipitation analyses suggested the interaction of cav-1 and ObR also in HASMCs. In a recent study, leptin was found to dose dependently up-regulate cav-1 expression in adipocytes, and adenoviral cav-1 overexpression impaired leptin signalling in fat cells. 36 In HASMCs, we did not detect any effects of short-term leptin stimulation on total cav-1 protein levels. Instead, leptin time dependently induced cav-1 phosphorylation, which could be prevented by apoE down-regulation. Interestingly, previous studies found the absence of adipocyte apoE to be associated with altered caveolae composition and reduced cav-1 expression, 37 suggesting that changes in membrane integrity and caveolae composition may underlie the observed absence of vascular effects of leptin in mice or SMCs lacking apoE. Cav-1 is a major substrate of non-receptor tyrosine kinases, including Src. 38 Although apoE down-regulation did not affect the leptin-induced Src phosphorylation, it reduced the interaction of Src with cav-1, thus potentially impairing the activation of cav-1 and other downstream signals. For example, NADPH oxidases also interact with cav-1, and cav-1 has been shown to be crucial for the p47 phox translocation and O 2 2 formation in response to AngII. 39 Leptin also enhanced cav-1 membrane localization, a process involving cytoskeletal reorganization. 40 Although we did not further examine this possibility, previous studies could show that leptin may enhance stress fibre formation via Ras homologue gene family-dependent signalling pathways, thereby promoting VSMC hypertrophy 41 or cardiac fibroblast migration. 42 We also found that siRNA-mediated down-regulation of cav-1 prevents the effects of leptin on SMC proliferation. Importantly, cav-1 deficiency was found to be associated with atherosclerosis protection despite a more proatherogenic lipid profile, 43 whereas endothelial overexpression of cav-1 accelerated atherosclerotic lesion expansion. 44 In line with these findings, we show that cav-1 deficiency protected against neointima formation after FeCl 3 -induced carotid artery injury. Moreover and importantly, leptin failed to promote neointima hyperplasia in mice lacking cav-1, supporting a role for cav-1 as a potential downstream effector of apoE deficiency. In line with our findings, reduction of hypothalamic cav-1 was recently reported to be causally involved in the obesityassociated attenuation of leptin-induced STAT3 activation. 45 Taken together, our findings in different mouse strains and cultivated SMCs suggest that apoE and cav-1 are critically involved in mediating the vascular lesion-promoting effects of leptin. In particular, downregulation of apoE was found to reduce cav-1 phosphorylation and to impair the leptin-induced activation of signalling pathways involved in NADPH oxidase activation, ROS formation, and SMC proliferation. Future studies will have to elucidate the implications of our findings for other cell types and whether modulation of cellular apoE and/or cav-1 expression may be helpful in overcoming the leptin resistance associated with obesity.
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